< back to News

The European Parlament hosted IMPACT-AML project on the occasion of the international Congress “EU Digital Health and Cancer Care: from scientific evidence to policy impact”, organized by the IRCSS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” in collaboration with the Emilia-Romagna Region Delegation to the EU and Euregha, and supported by the FLUTE and IMPACT-AML projects. The event focused on Impact AML and EP PerMed, two important European projects: the first aimed at advancing research and therapeutic strategies for relapsed refractory acute myeloid leukemia and the second dedicated to the topic of personalized medicine.

During the conference, Oriana Nanni, Project Coordinator at IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” – IRST S.r.l., delivered a presentation entitled “A pan-European framework for evidence-based cancer care: the IMPACT-AML approach”. IMPACT-AML focuses on relapsed or refractory acute myeloid leukaemia (R/R AML), a high-impact disease for which no standard of care exists and where there is an urgent need for new evidence on potential therapies. The aim of IMPACT-AML is to create an innovative and comprehensive framework to help define future standards of care and ultimately improve patient outcomes.

IMPACT AML is coordinated by Istituto Romagnolo per lo Studio dei Tumori ‘Dino Amadori’ – IRST IRCCS di Meldola and the University of Bologna, and is supported by a European call for tenders worth 6 million euros. The project seeks to establish a comprehensive framework for patients affected by relapsed or refractory acute myeloid leukaemia, facilitating the comparison of treatment regimens and creating a broad recruitment network. It combines the tools of clinical trials with personalised medicine to develop an inclusive regulatory framework for patients with relapsed or refractory acute myeloid leukaemia in multicentre, multinational clinical trials.

The meeting concluded with an open discussion on the future of cancer research in Europe. Gianni D’Errico, Head of the Project Management Office at Fondazione Toscana Life Sciences (TLS), presented EP PerMed, the largest European initiative dedicated to personalised medicine. The initiative brings together over 50 international partners and is co-financed by the European Commission with a budget of 335 million euros over 10 years. Involving 24 European and non-European countries, the project was established with the ambition of becoming a global platform for precision medicine through research, development, innovation and implementation of personalised approaches for the benefit of patients, citizens and society.

On the second day of the conference, a delegation from Italian regions including Emilia-Romagna, Tuscany, Veneto and Lazio, together with representatives of leading centres of excellence such as Fondazione TLS, met with the Honorable Stefano Bonaccini at the European Parliament, along with Honorable Raffaele Topo and Alessandra Moretti.

The meeting was attended by Giovanni Tonon, Director of the Center for Omics Sciences at San Raffaele IRCCS; Antonio Rosato, Scientific Director at IOV – Veneto Institute of Oncology; Paolo Mariotti, Head of the Research and Innovation Unit and International Cooperation and Head of the IRST Brussels Liaison Office at IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori” – IRST S.r.l.; and Alfredo Cesario, CEO and COO of Gemelli Digital Medicine & Health – Policlinico Gemelli.

This international stage marks an important step in highlighting how IMPACT-AML is contributing to the global dialogue on innovative, patient-centred cancer research.